Skip to main content
Signal8
Launch Terminal

Edgewise Therapeutics, Inc. (EWTX)

Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc.

NASDAQ:EWTXHealthcare
-0.03%$38.90
AH$39.10+0.51%vs close
Mkt Cap$4.22B
Float70.49M
O/S108.6M
Vol
$ Vol
RVOL
Inst Own-
SI16.7%
Earnings
Dilution
Edgewise Therapeutics, Inc. logoNASDAQ:EWTX$38.90-0.03%
FormDescription
4
PRIMARY DOCUMENT
4/A
PRIMARY DOCUMENT
4/A
PRIMARY DOCUMENT
4/A
PRIMARY DOCUMENT
4/A
PRIMARY DOCUMENT
4/A
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
13G/A
Beneficial Ownership Report (Amended)
13G/A
Beneficial Ownership Report (Amended)
13G/A
Beneficial Ownership Report (Amended)
144
Notice of Proposed Sale of Securities
13G
Beneficial Ownership Report
10-Q
Quarterly Report
8-K
2.02,9.01
4
PRIMARY DOCUMENT
8-K/A
9.01
1
8-K
2.01,7.01,9.01
1
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
144
Notice of Proposed Sale of Securities

1-25 of 419

…